Key Highlights

  • 7.05% is the indicated pre-market gain for Caris Life Sciences, Inc. (NASDAQ:CAI) on November 17, 2026, lifting the price to USD 22.48 from a calculated prior close of USD 21.00, a USD 1.48 move.
  • 27% is the year-over-year Revenue growth in the third quarter of 2026, as USD 275.4 million compared with USD 216.8 million, while Net Income fell to USD 15.3 million from USD 24.3 million.
  • 28% to 29% is the implied 2026 revenue growth over 2025 from raised guidance of USD 1.04 billion to USD 1.05 billion, announced on November 4, 2026, up from the prior USD 1.03 billion to USD 1.04 billion.
  • 374.2 million is the calculated net cash position in US dollars, built from USD 665.3 million of cash, USD 102.1 million of marketable securities and USD 393.2 million of long-term Debt at September 30, 2026.

What Moved Caris Life Sciences, Inc. (NASDAQ:CAI) in Pre-Market Trading on November 17, 2026 (+USD 1.48, +7.05%)

The indicated pre-market price is USD 22.48, a pre-market move of +7.05%. The calculated prior close is USD 21.00 (USD 22.48 divided by 1.0705), and the calculated USD move is +USD 1.48. Pre-market Volume was not found, and quotes before the 9:30 a.m. ET open can be thinner than regular-session trading. The company is listed on Nasdaq and has also announced a dual listing on NYSE Texas, effective June 17, 2026.

The Rationale: No Same-Day Catalyst After Raised Guidance for Caris Life Sciences, Inc. (NASDAQ:CAI)

No catalyst dated November 17, 2026 was identified in published coverage. On November 4, 2026 the company reported third quarter revenue of USD 275.4 million, up 27%, with molecular profiling services revenue of USD 262.7 million. Clinical cases were about 61,500, up 21%, with more than 358,000 total oncology tests. Gross Margin was 66% versus 68%, and Earnings were USD 0.05 per share versus USD 0.09 basic and USD 0.08 diluted. Founder and CEO David Dean Halbert called it another record quarter. As general context, a rebound after a post-earnings decline can reflect repositioning rather than new information.

Valuation, Liquidity and Risks for Caris Life Sciences, Inc. (NASDAQ:CAI)

Cash, equivalents and restricted cash of USD 665.3 million plus USD 102.1 million of marketable securities total a calculated USD 767.4 million, against USD 393.2 million of long-term debt, a calculated net cash position of about USD 374.2 million. The calculated net margin was 5.6% in the third quarter versus 11.2% a year earlier. Second quarter revenue was USD 263.7 million with about 59,200 cases, and a USD 100 million share repurchase program was announced earlier in 2026. Risks include margin compression, reimbursement, competition in molecular profiling and the high expectations embedded in a fast-growth healthcare name.

Where Things Stand

Caris Life Sciences, Inc. (NASDAQ:CAI) is indicated up 7.05% in pre-market trading on November 17, 2026, at USD 22.48, a calculated gain of USD 1.48 from a prior close of USD 21.00. No same-day catalyst was identified in published coverage. The most recent results, reported on November 4, 2026, showed revenue of USD 275.4 million, net income of USD 15.3 million and raised 2026 revenue guidance of USD 1.04 billion to USD 1.05 billion. Cash and marketable securities of a calculated USD 767.4 million offset USD 393.2 million of long-term debt. Pre-market moves can reverse quickly, and this article is informational and is not Investment advice.